Ukr.Biochem.J. 2017; Volume 89, Issue 6, Nov-Dec, pp. 48-55


Effect of L-carnitine administration on serum insulin and adiponectin levels, and AMPK, APPL1 and PPARγ gene expression in STZ-induced diabetic rat liver

B. Shahouzehi1, K. Barkhordari2, S. Aminizadeh3, Y. Masoumi-Ardakani4*

1Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;
2Department of Virology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran;
3Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;
4Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Iran;

Diabetes is considered as a metabolic disease in which insulin secretion and functions are disturbed and characterized by hyperglycemia. L-carnitine is synthesized in most mammals and plays critical role in fatty acid oxidation and energy production. Data about the L-carnitine hypoglycemic effects are controversial. We evaluated long-term oral L-carnitine administration effects on blood glucose, insulin and adiponectin levels, as well as expression of AMPK, APPL1 and PPARγ genes in liver of STZ-induced diabetic rats. Group 1 (control), did not receive any treatment, group 2 received 50 mg/kg STZ by i.p injection, group 3 received single dose of 50 mg/kg STZ by i.p injection and also 600 mg/kg/day L-carnitine orally for 5 weeks. Our results showed that L-carnitine long-term oral supplementation significantly reduced blood glucose and normalized insulin levels in diabetic rats. Also, we found that L-carnitine significantly increased AMPK and APPL1 expression, and showed a mild elevation of PPARγ expression. In sum, we suggest that long-term L-carnitine supplementation has beneficial effects on diabetic rats which showed hypoglycemic effects. Probably the beneficial effects of L-carnitine are contributed to the upregulation of insulin sensitizers such as AMPK and adiponectin.

Keywords: , , , , ,


  1. Abdel-Razek H. A. D. Beneficial effect of L-carnitine on the neuromuscular performance in diabetic rats. Menoufia Med J. 2010;23:159-173.
  2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49.  PubMed, CrossRef
  3. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract. 2008 Feb;23(1):16-34. PubMed, CrossRef
  4. Leibovitz B., Mueller J. Carnitine. J Optimal Nutr. 1993; 2(2): 90-109.
  5. Alipour B, Barzegar A, Panahi F, Safaeian A, Eshaghi M.  Effect of L-Carnitine Supplementation on Metabolic Status in Obese Diabetic Women With Hypocaloric Diet.  Health Scope. 2014; 3(1): e14615.  CrossRef
  6. Ramsay RR. The carnitine acyltransferases: modulators of acyl-CoA-dependent reactions. Biochem Soc Trans. 2000 Feb;28(2):182-6. PubMed, CrossRef
  7. Bin Aleem S, Hussain MM, Farooq Y. Serum levo-carnitine levels and skeletal muscle functions in type 2 diabetes mellitus in rodents. J Coll Physicians Surg Pak. 2013 Feb;23(2):132-6.  PubMed
  8. Cha YS. Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. Asia Pac J Clin Nutr. 2008;17 Suppl 1:306-8. PubMed
  9. Hadadinezhad S, Ghazaleh N, Razavi Z. Effects of L-Carnitine on Glycemic Control and C-Peptide Levels in Patients with Type 2 Diabetes Mellitus. Turk Jem. 2008; 12(1):1-3.
  10. Rodrigues B, Xiang H, McNeill JH. Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes. 1988 Oct;37(10):1358-64. PubMed, CrossRef
  11. Xia Y, Li Q, Zhong W, Dong J, Wang Z, Wang C. L-carnitine ameliorated fatty liver in high-calorie diet/STZ-induced type 2 diabetic mice by improving mitochondrial function. Diabetol Metab Syndr. 2011 Nov 15;3:31.  PubMed, PubMedCentral, CrossRef
  12. Lim CT, Kola B, Korbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol. 2010 Feb;44(2):87-97. PubMed, CrossRef
  13. Janani C, Ranjitha Kumari BD. PPAR gamma gene – a review. Diabetes Metab Syndr. 2015 Jan-Mar;9(1):46-50. PubMed, CrossRef
  14. Lee WH, Kim SG. AMPK-Dependent Metabolic Regulation by PPAR Agonists. PPAR Res. 2010;2010. pii: 549101.  PubMed, PubMedCentral, CrossRef
  15. Patel J, Goyal R, Bhatt P. Beneficial effects of levo-carnitine on lipid metabolism and cardiac function in neonatal streptozotocin rat model of diabetes.  Int J Diabetes Metabolism. 2008; 16:29-34.
  16. Bazotte RB, Lopes-Bertolini G. Effects of oral L-carnitine and DL-carnitine supplementation on alloxan-diabetic rats. Braz Arch Biol Technol. 2012; 55(1): 81-88.  CrossRef
  17. Najafipour H, Vakili A, Shahouzehi B, Soltani Hekmat A, Masoomi Y, Yeganeh Hajahmadi M, Esmaeli-Mahani S. Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension. J Physiol Biochem. 2015 Jun;71(2):165-75.  PubMed, CrossRef
  18. Mansour HH.  Effect of L-Carnitine on Endothelial Dysfunction markers in Diabetic-Irradiated rats.  Int J Toxicol Appl Pharmacol. 2013;3(1):1-9.
  19. Malone JI, Schocken DD, Morrison AD, Gilbert-Barness E. Diabetic cardiomyopathy and carnitine deficiency. J Diabetes Complications. 1999 Mar-Apr;13(2):86-90. PubMed, CrossRef
  20. Uysal N, Yalaz G, Acikgoz O, Gonenc S, Kayatekin BM. Effect of L-carnitine on diabetogenic action of streptozotocin in rats. Neuro Endocrinol Lett. 2005 Aug;26(4):419-22. PubMed
  21. Aoshima S, Fujisawa S, Kobayashi A. Changes in the subcellular distribution of free carnitine and its acyl derivatives in diabetic rat hearts following treatment with L-carnitine. Jpn Heart J. 1993 Nov;34(6):763-72. PubMed, CrossRef
  22. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008 Dec;32 Suppl 7:S13-8.  PubMed, CrossRef
  23. Shahouzehi B, Shokoohi M, Najafipour H. The effect of opium addiction on serum adiponectin and leptin levels in male subjects: a case control study from Kerman Coronary Artery Disease Risk Factors Study (KERCADRS). EXCLI J. 2013 Oct 30;12:916-23. PubMed, PubMed
  24. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, Winegar DA, Strum JC, Stimpson SA, Pahel GL. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol. 2004 Oct 18;4:23. PubMed, PubMedCentral, CrossRef
  25. Rogue A, Spire C, Brun M, Claude N, Guillouzo A. Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. PPAR Res. 2010;2010:325183.  PubMed, PubMedCentral, CrossRef
  26. Deepa SS, Zhou L, Ryu J, Wang C, Mao X, Li C, Zhang N, Musi N, DeFronzo RA, Liu F, Dong LQ. APPL1 mediates adiponectin-induced LKB1 cytosolic localization through the PP2A-PKCzeta signaling pathway. Mol Endocrinol. 2011 Oct;25(10):1773-85. PubMed, PubMedCentral, CrossRef
  27. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E22-36.  PubMed, PubMedCentral, CrossRef
  28. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, Fang Q, Christ-Roberts CY, Hong JY, Kim RY, Liu F, Dong LQ. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006 May;8(5):516-23. PubMed, CrossRef
  29. Odo S, Tanabe K, Yamauchi M. A Pilot Clinical Trial on L-Carnitine Supplementation in Combination with Motivation Training: Effects on Weight Management in Healthy Volunteers. Food  Nutr Sci. 2013; 4(2):222-231. CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.